Replies to post #16203 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

MNTA has designed around ABBV's Humira-formulation patents, according to CW. So, with ABBV's US composition-of-matter patent on Humira soon to expire, ABBV's protection from FoB competition in the US market would seem to boil down to its various "method of use" (i.e. indication-specific) patents.

Please see #msg-118781959 for related info.

[DewDiligence]

UK Court invalidates ABBV’s Humira “use” patents on three indications:

#msg-129261201